Contact Us
Drug Search Results
Using advanced filters...
Advanced Search [+]

Niclosamide

Alternative Names: niclosamide, atx-201, atx201, atx 201, niclocide, FW-ICI-AC
Latest Update: 2025-02-03
Latest Update Note: Clinical Trial Update

Product Description

Niclosamide is an anthelmintic drug that has been used for over 50 years mainly to treat tapeworm infections. However, with the increase in drug repurposing initiatives, niclosamide has emerged as a true hit in many screens against various diseases. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/29603892/)

Mechanisms of Action: STAT3 Inhibitor,mTOR Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral,Topical

FDA Designation: None *

Approval Status: Approved

Approved Countries: Bangladesh | Belgium | Chile | Colombia | Dominican Republic | Egypt | France | Germany | Greece | Hong Kong | India | Italy | Korea | Lebanon | Luxembourg | Malta | Morocco | Netherlands | New Zealand | Pakistan | Peru | Portugal | Russia | Sweden | Taiwan | Thailand | Turkey | United Kingdom | Vietnam

Approved Indications: None

Known Adverse Events: None

Company: UNION therapeutics
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Niclosamide

Countries in Clinic: Australia, United Kingdom

Active Clinical Trial Count: 3

Highest Development Phases

Phase 3: COVID-19

Phase 2: Proctitis

Phase 1: Zika Virus Infection

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
PROTECT-V

P3

Recruiting

COVID-19

2024-07-01

ND

P2

Active, not recruiting

Proctitis

2019-03-07

AWP MDFF

P1

Not yet recruiting

Zika Virus Infection

None

Recent News Events

Date

Type

Title

09/11/2024

News Article

 Hyundai Bioscience announces XAFTY®, a groundbreaking broad-spectrum antiviral capable of treating COVID-19, mpox, and dengue

07/11/2024

News Article

 ADM Korea Announces Niclosamide-based Metabolic Anticancer Drug's First Clinical Trial Target as 'Prostate Cancer Patients Resistant to Hormone Therapy'

04/25/2024

News Article

 Hyundai Bioscience's antiviral for Dengue Fever to enter clinical trials in Brazil

04/25/2024

News Article

 Hyundai Bioscience Announces Clinical Development Plan for Niclosamide-based Metabolic Anticancer Drug Targeting P53 Mutation Cancer

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you've used PRYZM, we hope you're able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions